Managing Chemotherapy patients during the COVID-19 crisis – A Clinical Pharmacy Congress Webinar in Partnership with BOPA

A Clinical Pharmacy Congress Webinar in Partnership with BOPA

 

Speaker – Steve Williamson, Lead Cancer Pharmacist, NHS England and NHS Improvement and previous Chair of BOPA

 

Discussion of the interim chemotherapy treatment options funded during the crisis and the NHS England / NICE clinical guidelines.

Will provide a run-through of how the NHS in England managed the commissioning of new interim chemotherapy treatments to benefit patients during COVID-19 including

• Discussion of the rationale for why treatments were chosen
• Discussion of the clinical benefits tool that was developed to inform decision making
• Presentation of the latest uptake figures for interim treatments
• Discussion of how things will change in future

 

Register and see event page HERE

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article